Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

Kentaro To; Noriko Miyake; Yoji Nagasaki; Nobuyuki Shimono

Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

Kentaro To, Noriko Miyake, Yoji Nagasaki, Nobuyuki Shimono

Research output: Contribution to journal › Article › peer-review

Abstract

Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

Original language	English
Pages (from-to)	389-394
Number of pages	6
Journal	Japanese Journal of Antibiotics
Volume	64
Issue number	6
Publication status	Published - Dec 1 2011

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{d6030c624eee4e64a9f6dd6c4b9562bc,

title = "Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA",

abstract = "Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.",

author = "Kentaro To and Noriko Miyake and Yoji Nagasaki and Nobuyuki Shimono",

year = "2011",

month = dec,

day = "1",

language = "English",

volume = "64",

pages = "389--394",

journal = "The Journal of antibiotics. Ser. B",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "6",

}

TY - JOUR

T1 - Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

AU - To, Kentaro

AU - Miyake, Noriko

AU - Nagasaki, Yoji

AU - Shimono, Nobuyuki

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

AB - Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

UR - http://www.scopus.com/inward/record.url?scp=84856173794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856173794&partnerID=8YFLogxK

M3 - Article

C2 - 22686009

AN - SCOPUS:84856173794

SN - 0368-2781

VL - 64

SP - 389

EP - 394

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

IS - 6

ER -

Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this